Pharming Group (PHAR) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Pharming Group is expected to report Q3 2026 results on Tuesday, October 27. Analysts forecast earnings of $0.15 per share and revenue of $117.6 million, while the company previously missed quarterly EPS estimates.
• The company raised its Q3 revenue guidance to $117.6 million and expects full-year 2026 revenue of $380 million to $390 million, broadly in line with analyst consensus.
• Analyst sentiment remains mixed: HC Wainwright maintains a Buy rating and a $37 price target, while other firms have issued Hold or Sell ratings. The stock recently traded at $11.20, up 5%, but remains well below its 52-week high of $21.34.

Pharming Group (NASDAQ:PHAR - Get Free Report) is expected to be issuing its Q3 2026 TU results before the market opens on Tuesday, October 27th. Analysts expect the company to post earnings of $0.15 per share and revenue of $117.60 million for the quarter. Parties may visit the company's upcoming Q3 2026 TU earnings overview page for the latest details on the call scheduled for Thursday, October 22, 2026 at 1:00 AM ET.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, analysts expect Pharming Group to post $0.32 EPS for the current fiscal year and $0.28 EPS for the next fiscal year.

Pharming Group Stock Up 5.0%

Pharming Group stock opened at $11.20 on Friday. The stock has a market cap of $792.71 million, a price-to-earnings ratio of 93.33 and a beta of -0.05. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. The company's 50-day moving average price is $10.67 and its two-hundred day moving average price is $12.62. Pharming Group has a 52 week low of $9.11 and a 52 week high of $21.34.

Key Headlines Impacting Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Pharming raised its third-quarter 2026 revenue guidance to $117.6 million, well above the $103.4 million analyst consensus. It also forecast full-year 2026 revenue of $380 million to $390 million, broadly in line with the $382.1 million consensus, supporting expectations for continued commercial growth.
• Positive Sentiment: HC Wainwright lifted its Q3 2026 EPS forecast to $0.45 from $0.23 and increased its FY2026 estimate to $0.45 from $0.43. The firm also raised its FY2027 estimate to $0.56 from $0.54, retained a Buy rating, and maintained a $37 price target—well above the stock’s recent trading level. MarketBeat Pharming Group analyst estimates
• Positive Sentiment: Recent analyst coverage has highlighted Pharming among bullish healthcare-stock ideas, potentially improving investor sentiment and increasing attention around the company’s revenue growth and earnings outlook. Analysts are bullish on Pharming Group Analyst insights on Pharming Group
• Negative Sentiment: HC Wainwright sharply cut its Q4 2026 EPS forecast to $0.00 from $0.24. While the analyst still rates the shares Buy and raised its full-year outlook, the lowered fourth-quarter estimate signals potential earnings volatility and may limit the stock’s upside.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, September 22nd. Zacks Research cut shares of Pharming Group from a "hold" rating to a "strong sell" rating in a report on Friday, July 31st. Weiss Ratings reiterated a "sell (d)" rating on shares of Pharming Group in a research note on Friday, August 7th. Wall Street Zen raised Pharming Group to a "hold" rating in a report on Saturday. Finally, Canaccord Genuity Group set a $38.00 target price on Pharming Group in a report on Wednesday, September 23rd. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Pharming Group currently has an average rating of "Hold" and a consensus target price of $38.67.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming's principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.